Acorda Therapeutics to Acquire Civitas Therapeutics

From NeurologyWire

Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinsons disease (PD). The acquisition also includes rights to Civitas proprietary ARCUSTM pulmon...

Login to read story

Thursday, October 30, 2014

Show last days of articles

Parkinson's drug gets OK for Phase III

From NeurologyWire

The Israeli drug development company IntecPharma has secured Food & Drug Administration approval for a Phase III clinical trial on its Parkinsons dise...Full story

Molecular map reveals genetic origins of 21 autoimmune disea...

From NeurologyWire

Scientists have created a molecular map that pinpoints genetic variants that play a role in 21 different autoimmune diseases, they report Oct. 27 in t...Full story

Low-carb, high-fat diets may reduce seizures in tough-to-tre...

From NeurologyWire

Diets high in fat and low in carbohydrates, such as the ketogenic or modified Atkins diet, may reduce seizures in adults with tough-to-treat epilepsy,...Full story

Bariatric surgery may lead to severe headaches

From NeurologyWire

Bariatric surgery may be a risk factor for a condition that causes severe headaches, according to a study published in the October 22, 2014, online is...Full story

Wednesday, October 29, 2014

Duchenne Muscular Dystrophy drug publishes Phase 2b Data in ...

From NeurologyWire

PTC Therapeutics announced the publication of data and related analysis which provide strong support for concluding that Translarna (ataluren) was act...Full story

Tuesday, October 28, 2014

Synapses Always on the Starting Blocks

From NeurologyWire

While neurons rapidly propagate information in their interior via electrical signals, they communicate with each other at special contact points known...Full story

DEA removes pain drug from control schedule

From NeurologyWire

The Drug Enforcement Agency will remove Naloxegol and its salts from the schedules of the Controlled Substances Act (CSA). Naloxegol is currently a sc...Full story

Small fiber neuropathy drug fast-tracked by FDA

From NeurologyWire

Araim Pharmaceuticals says it received a Fast Track Designation from the FDA for its lead compound ARA290, for treatment of Sarcoidosis-associated Sma...Full story

Monday, October 27, 2014

Activity in Dendrites is Critical in Memory Formation

From NeurologyWire

Why do we remember some things and not others? In a unique imaging study, two Northwestern University researchers have discovered how neurons in the b...Full story

FDA seeks more data on Sarepta muscle disorder drug

From NeurologyWire

Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had asked for additional data on its lead drug, delaying its marketing application...Full story

Study offers first look at how NCAA concussion guidelines ar...

From NeurologyWire

Though most NCAA colleges and universities have created programs to help athletes deal with concussions, a new Harvard study has found that, when it c...Full story

Friday, October 24, 2014

Cost of stroke care does not decrease over long-term

From NeurologyWire

Costs to treat strokes caused by bleeding in the brain may increase significantly 10 years later, according to a study in the American Heart Associati...Full story

Thursday, October 23, 2014

Why people with Down Syndrome invariably develop Alzheimers

From NeurologyWire

A new study by researchers at Sanford-Burnham Medical Research Institute reveals the process that leads to changes in the brains of individuals with D...Full story

Stem cell procedure rescued spatial learning and memory defi...

From NeurologyWire

The first data in a study transplanting neural stem cells in an animal model of Alzheimer's disease found that the cells rescued spatial learning and ...Full story

Non-invasive VNS for headache therapy sees results

From NeurologyWire

Preliminary results of an open-label trial carried in the journal of Headache and Pain reported that a single treatment with electroCores hand held no...Full story